Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
13%
Ph phase_3
1
13%
Ph phase_1
1
13%
Ph phase_2
5
63%

Phase Distribution

1

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
5(62.5%)
Phase 3Large-scale testing
1(12.5%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(1)
Other(7)

Detailed Status

unknown7
Completed1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 25 (62.5%)
Phase 31 (12.5%)
N/A1 (12.5%)

Trials by Status

completed113%
unknown788%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

NCT02845908
unknownnot_applicable

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

NCT04174339
unknownphase_2

POF Versus FOLFOX Plus IP Paclitaxel in AGC

NCT04155671
unknownphase_3

A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

NCT03788226
unknownphase_2

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

NCT04121039
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02845908Phase 2

POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

Completed
NCT04174339Not Applicable

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Unknown
NCT04155671Phase 2

POF Versus FOLFOX Plus IP Paclitaxel in AGC

Unknown
NCT03788226Phase 3

A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

Unknown
NCT04121039Phase 2

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

Unknown
NCT03788174Phase 2

Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma

Unknown
NCT03707639Phase 2

Study of the Combination of Apatinib and POF

Unknown
NCT03244774Phase 1

Phase I Study of the Combination of Apatinib and POF

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8